JAGSNPHARMJagsonpal Pharmaceuticals Limited
NSE · Healthcare · Small Cap · Mkt cap ₹16.9B · Vol 44.80M
₹1,301.04
▲ +1.19% today
Fetching live price…
God's Eye forensics
Accounting quality and solvency screens. Anything that can't be computed from available filings data is left blank rather than estimated.
Piotroski F-Score
5/55
5 of 5 financial-health checks passed (4 checks need data this provider doesn't publish).
Altman Z-Score
Insufficient data—
Needs total assets, operating profit and debt — not published for this listing yet.
Beneish (earnings quality)
Insufficient data—
The full manipulation model needs two years of receivables, depreciation and accrual data, which isn't published for this listing.
Scores are free. The criteria-by-criteria breakdown — exactly which checks this company failed — is part of DeepScreen Pro.
Fundamental breakdown — raw ratios are free · fetching live data — showing modeled estimates for now
P/E Ratio (TTM)
Modeled19.8x
Fairly priced
Contextual insight — DeepScreen Pro
PEG Ratio
Modeled1.66
Overvalued vs. growth
Contextual insight — DeepScreen Pro
P/S Ratio
Modeled2.53x
Moderate
Contextual insight — DeepScreen Pro
P/B Ratio
Modeled6.38x
Typical for the sector
Contextual insight — DeepScreen Pro
EV/Revenue
Modeled2.81x
Low for an asset-light business
Contextual insight — DeepScreen Pro
EV/EBITDA
Modeled11.9x
Low for asset-light
Contextual insight — DeepScreen Pro
ROE
Modeled32.2%
Excellent shareholder returns
Contextual insight — DeepScreen Pro
ROA
Modeled16.1%
Strong for asset-light
Contextual insight — DeepScreen Pro
ROCE
Modeled24.9%
High-quality compounder
Contextual insight — DeepScreen Pro
Debt / Equity
Modeled0.65x
Manageable
Contextual insight — DeepScreen Pro
LT Debt / Equity
Modeled0.55x
Moderate long-term leverage
Contextual insight — DeepScreen Pro
Payout Ratio
Modeled24%
Growth company — reinvesting most profit
Contextual insight — DeepScreen Pro
Operating Leverage
Modeled2.17x
Good upside gearing
Contextual insight — DeepScreen Pro
Company financials
- EPS (TTM)
- ₹65.71
- Revenue (TTM)
- ₹6.7B
- Net margin
- 12.8%
- EBITDA margin
- 23.6%
- Earnings growth
- 11.9%
- Dividend yield
- 1.21%
- Payout ratio
- 24%
- Debt / equity
- 0.65x
Live data hasn't loaded yet — figures shown are DeepScreen's modeled estimates.
JAGSNPHARM live news
LIVELoading live headlines…